Trial intelligence / Profile preview

Phase II cediranib for malignant ascites or pleural effusion

NL-OMON35120Phase 2Recruiting

Sponsor
Radboud University Medical Center
Start
Apr 2010
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial of cediranib in malignant ascites and malignant pleural effusion (MPE), sponsored by Radboud University Medical Center. Started Apr 2010; status: recruiting.

02

Drugs

cediranib
03

Conditions

malignant ascitesmalignant pleural effusion (MPE)

Beyond the preview

Go deeper on NL-OMON35120.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NL-OMON35120.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call